Table 2.
Comparison of Side Effects of the PGRN-AMPS Eligible for Analysis Subset Who Received Citalopram (N=143) and STAR*D Subset Who Received Citalopram (N=1,483) at the Four Week Visi
| PGRN-AMPS | STAR*D | ||||
|---|---|---|---|---|---|
| N | % | N | % | P | |
| Side Effect Frequency | 0.005 | ||||
| None | 69 | 48.30 | 533 | 35.90 | |
| 10%–25% of the time | 43 | 30.10 | 534 | 36.00 | |
| 50%–75% of the time | 23 | 16.10 | 267 | 18.00 | |
| 90%–100% of the time | 8 | 5.60 | 149 | 10.00 | |
| Side Effect Intensity | 0.001 | ||||
| None | 68 | 47.60 | 526 | 35.50 | |
| Trivial-mild | 45 | 31.50 | 513 | 34.60 | |
| Moderate-marked | 30 | 21.00 | 365 | 24.60 | |
| Severe-intolerable | 0 | 0.00 | 79 | 5.30 | |
| Side Effect Burden | <0.0001 | ||||
| No impairment | 87 | 60.80 | 662 | 44.60 | |
| Minimal-mild impairment | 45 | 31.50 | 608 | 41.00 | |
| Moderate-marked impairment | 11 | 7.70 | 181 | 12.20 | |
| Severe impairment-unable to function | 0 | 0.00 | 32 | 2.20 | |